Overseeing research on therapeutic cloning: a private ethics board responds to its critics.

Ronald M. Green, Kier Olsen DeVries, Judith Bernstein, Kenneth W. Goodman, Robert Kaufmann, Ann A. Kiessling, Susan R. Levin, Susan L. Moss, Carol A. Tauer

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Advanced Cell Technology's Ethics Advisory Board has been called window dressing for a corporate marketing plan. But the scientists and managers have paid attention, and the lawyers have gone along.

Original languageEnglish (US)
Pages (from-to)27-33
Number of pages7
JournalThe Hastings Center report
Volume32
Issue number3
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Health(social science)
  • Issues, ethics and legal aspects
  • Philosophy
  • Health Policy

Cite this

Green, R. M., DeVries, K. O., Bernstein, J., Goodman, K. W., Kaufmann, R., Kiessling, A. A., Levin, S. R., Moss, S. L., & Tauer, C. A. (2002). Overseeing research on therapeutic cloning: a private ethics board responds to its critics. The Hastings Center report, 32(3), 27-33. https://doi.org/10.2307/3528111